.png){kind=icon}
.png){kind=icon}
Return
Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia: A validation study
.png){kind=icon}
PRE
AI
DOI：10.1016/j.preghy.2025.101239.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• The combination of PlGF, PAPP-A, and maternal factors enables prediction of early onset and preterm preeclampsia with low false-positive rate. • At 20% false-positive rate, 80% early-onset, 68% preterm, and 58% term preeclampsia cases can be predicted. • These findings support expanding multiple marker prenatal screening to incorporate preeclampsia risk prediction.
Keywords:
PlGF
PAPP-A
preeclampsia
prenatal screening
biomarkers
Journal
P
IF:
0
Papers:
202
Citations:
2